January 02, 2014 07:30 AM Eastern Standard Time
POZEN ($POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced the promotion of Dennis McNamara to Senior Vice President and Chief Business Officer. Mr. McNamara is responsible for leading corporate development, alliance management and intellectual property efforts at POZEN. Prior to this appointment, Mr. McNamara held the position of Vice President, Business Development at POZEN, where he has been instrumental in successfully licensing POZEN's products and product candidates to major pharmaceutical companies, including GlaxoSmithKline, AstraZeneca AB, sanofi-aventis U.S. LLC, Horizon Pharma US, Inc., and Cilag GmbH International.
"The Board of Directors and I are pleased to appoint Dennis as Chief Business Officer," said Dr. John Plachetka, Chairman, President and Chief Executive Officer of POZEN. "He has been an exceptional employee throughout the years and we look forward to working with Dennis in his new and expanded role."
POZEN Inc. is a small pharmaceutical company that specializes in developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products in two years. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.
POZEN is currently seeking strategic partners to help maximize the opportunities for its portfolio assets.
The Company's common stock is traded under the symbol "POZN" on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit .